Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon
This study has been completed.
Study NCT00048763   Information provided by Otsuka America Pharmaceutical
First Received: November 7, 2002   Last Updated: July 14, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Raynaud's Disease
Additional conditions recognized in this trial
Raynaud Disease
More general conditions related to this trial
Cardiovascular Diseases
Peripheral Vascular Diseases
Vascular Diseases
Interventions listed in this trial
Pletal
Additional drug interventions recognized in this trial
Cilostazol
More general drug interventions related to this trial
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cardiovascular Agents
Central Nervous System Agents
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Protective Agents
Respiratory System Agents
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Otsuka America Pharmaceutical


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services